{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:38:04Z","timestamp":1790865484001,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Key Clinical Specialist Construction Programs"},{"name":"High-level Public Health Technology Talent Construction Project","award":["Academic Leader-02-29"],"award-info":[{"award-number":["Academic Leader-02-29"]}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program","doi-asserted-by":"crossref","award":["2024YFC2311203"],"award-info":[{"award-number":["2024YFC2311203"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Special Project of Guangzhou National Laboratory for 2024- Short Term Treatment of Tuberculosis","award":["GZNL2024A01030"],"award-info":[{"award-number":["GZNL2024A01030"]}]},{"name":"Global Tuberculosis Drug Research and Development Alliance Cooperation Project of China Anti-TB Association","award":["CATA\/TBA-20210310HQ7"],"award-info":[{"award-number":["CATA\/TBA-20210310HQ7"]}]},{"name":"Beijing Clinical Medicine Development Special Project \"Sailing 3.0\"","award":["ZLRK202331"],"award-info":[{"award-number":["ZLRK202331"]}]},{"name":"Beijing Municipal Health Commission Research Ward Excellent Clinical Research Program","award":["BRWEP2024W042160109"],"award-info":[{"award-number":["BRWEP2024W042160109"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-12869-8","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T09:54:02Z","timestamp":1771062842000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Acquired linezolid resistance in DR-TB: genotype-phenotype discordance and molecular heterogeneity in a retrospective cohort"],"prefix":"10.1186","volume":"26","author":[{"given":"Wenqiang","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naihui","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"key":"12869_CR1","volume-title":"Global tuberculosis report 2025 [M]","author":"World Health Organization","year":"2025","unstructured":"World Health Organization. Global tuberculosis report 2025 [M]. Geneva: World Health Organization; 2025."},{"key":"12869_CR2","volume-title":"WHO consolidated guidelines on drug-resistant treatment [M]","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. WHO consolidated guidelines on drug-resistant treatment [M]. Geneva: World Health Organization; 2019."},{"issue":"10150","key":"12869_CR3","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","volume":"392","author":"N Ahmad","year":"2018","unstructured":"Ahmad N, Ahuja SD, Akkerman OW, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis [J]. Lancet. 2018;392(10150):821\u201334.","journal-title":"Lancet"},{"key":"12869_CR4","volume-title":"WHO consolidated guidelines on tuberculosis: module 4: Treatment-Drug-resistant tuberculosis treatment [M]","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: Treatment-Drug-resistant tuberculosis treatment [M]. Geneva: World Health Organization; 2022."},{"issue":"10","key":"12869_CR5","first-page":"988","volume":"45","author":"T Shenjie","year":"2022","unstructured":"Shenjie T, Liang L, Lan Y. Consensus on linezolid in the treatment of tuberculosis(2022 update) [J]. Chin J Tuberc Respir Dis. 2022;45(10):988\u201395.","journal-title":"Chin J Tuberc Respir Dis"},{"issue":"8","key":"12869_CR6","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/jac\/dkz206","volume":"74","author":"S Wasserman","year":"2019","unstructured":"Wasserman S, Louw G, Ramangoaela L, et al. Linezolid resistance in patients with drug-resistant TB and treatment failure in South Africa [J]. J Antimicrob Chemother. 2019;74(8):2377\u201384.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"12869_CR7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4103\/ijmr.IJMR_1168_19","volume":"154","author":"R Nambiar","year":"2021","unstructured":"Nambiar R, Tornheim JA, Diricks M, et al. Linezolid resistance in Mycobacterium tuberculosis isolates at a tertiary care centre in Mumbai, India [J]. Indian J Med Res. 2021;154(1):85\u20139.","journal-title":"Indian J Med Res"},{"key":"12869_CR8","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jgar.2023.05.001","volume":"34","author":"Q An","year":"2023","unstructured":"An Q, Lin R, Yang Q, et al. Evaluation of genetic mutations associated with phenotypic resistance to fluoroquinolones, bedaquiline, and linezolid in clinical Mycobacterium tuberculosis: A systematic review and meta-analysis [J]. J Glob Antimicrob Resist. 2023;34:214\u201326.","journal-title":"J Glob Antimicrob Resist"},{"issue":"8","key":"12869_CR9","doi-asserted-by":"publisher","first-page":"e00165","DOI":"10.1128\/AAC.00165-18","volume":"62","author":"Z Zong","year":"2018","unstructured":"Zong Z, Jing W, Shi J, et al. Comparison of in vitro activity and MIC distributions between the novel Oxazolidinone delpazolid and linezolid against Multidrug-Resistant and extensively drug-resistant Mycobacterium tuberculosis in China [J]. Antimicrob Agents Chemother. 2018;62(8):e00165\u201318.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"12869_CR10","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3390\/pathogens14030218","volume":"14","author":"J Dong","year":"2025","unstructured":"Dong J, Cheng Q, Tang C, et al. Comparative in vitro drug susceptibility study of five Oxazolidinones against Mycobacterium tuberculosis in Hainan. China [J] Pathogens. 2025;14(3):218.","journal-title":"China [J] Pathogens"},{"issue":"8","key":"12869_CR11","doi-asserted-by":"publisher","first-page":"e00751","DOI":"10.1128\/AAC.00751-17","volume":"61","author":"S Srivastava","year":"2017","unstructured":"Srivastava S, Magombedze G, Koeuth T, et al. Linezolid dose that maximizes sterilizing effect while minimizing toxicity and resistance emergence for tuberculosis [J]. Antimicrob Agents Chemother. 2017;61(8):e00751\u201317.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"12869_CR12","doi-asserted-by":"publisher","first-page":"e1013190","DOI":"10.1371\/journal.ppat.1013190","volume":"21","author":"H Zhang","year":"2025","unstructured":"Zhang H, Wang S, Zhang Y, et al. Mutations in the transcriptional regulator MAB_2885 confer tedizolid and linezolid resistance through the MmpS-MmpL efflux pump MAB_2302-MAB_2303 in Mycobacterium abscessus [J]. PLoS Path. 2025;21(5):e1013190.","journal-title":"PLoS Path"},{"key":"12869_CR13","volume-title":"Consultation on the definition of extensively drug-resistant tuberculosis, 27\u201329 October 2020 [M]","author":"Meeting report of the WHO expert","year":"2020","unstructured":"Meeting report of the WHO expert. Consultation on the definition of extensively drug-resistant tuberculosis, 27\u201329 October 2020 [M]. Geneva: World Health Organization; 2020."},{"key":"12869_CR14","volume-title":"Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis [M]","author":"World Health Organization","year":"2014","unstructured":"World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis [M]. Geneva: World Health Organization; 2014."},{"key":"12869_CR15","volume-title":"Global tuberculosis report 2019 [M]","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. Global tuberculosis report 2019 [M]. Geneva: World Health Organization; 2019."},{"issue":"3","key":"12869_CR16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ijantimicag.2013.12.007","volume":"43","author":"Z Zhang","year":"2014","unstructured":"Zhang Z, Pang Y, Wang Y, et al. Beijing genotype of Mycobacterium tuberculosis is significantly associated with linezolid resistance in multidrug-resistant and extensively drug-resistant tuberculosis in China [J]. Int J Antimicrob Agents. 2014;43(3):231\u20135.","journal-title":"Int J Antimicrob Agents"},{"key":"12869_CR17","doi-asserted-by":"publisher","first-page":"955050","DOI":"10.3389\/fphar.2022.955050","volume":"13","author":"T Azimi","year":"2022","unstructured":"Azimi T, Khoshnood S, Asadi A, et al. Linezolid resistance in multidrug-resistant Mycobacterium tuberculosis: A systematic review and meta-analysis [J]. Front Pharmacol. 2022;13:955050.","journal-title":"Front Pharmacol"},{"issue":"7","key":"12869_CR18","doi-asserted-by":"publisher","first-page":"567","DOI":"10.5588\/ijtld.22.0632","volume":"27","author":"D Vengurlekar","year":"2023","unstructured":"Vengurlekar D, Walker C, Mahajan R, et al. Linezolid resistance in patients with drug-resistant TB [J]. Int J Tuberc Lung Dis. 2023;27(7):567\u20139.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"10","key":"12869_CR19","doi-asserted-by":"publisher","first-page":"e01296","DOI":"10.1128\/AAC.01296-17","volume":"61","author":"MB McNeil","year":"2017","unstructured":"McNeil MB, Dennison DD, Shelton CD, et al. In vitro isolation and characterization of Oxazolidinone-Resistant Mycobacterium tuberculosis [J]. Antimicrob Agents Chemother. 2017;61(10):e01296\u201317.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"12869_CR20","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1093\/jac\/dkaa136","volume":"75","author":"S Kadura","year":"2020","unstructured":"Kadura S, King N, Nakhoul M, et al. Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, Delamanid and pretomanid [J]. J Antimicrob Chemother. 2020;75(8):2031\u201343.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"12869_CR21","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1128\/AAC.01113-06","volume":"51","author":"E Richter","year":"2007","unstructured":"Richter E, R\u00fcsch-Gerdes S, Hillemann D. First linezolid-resistant clinical isolates of Mycobacterium tuberculosis [J]. Antimicrob Agents Chemother. 2007;51(4):1534\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"12869_CR22","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1128\/AAC.00414-07","volume":"52","author":"T-S Huang","year":"2008","unstructured":"Huang T-S, Liu Y-C, Sy C-L, et al. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years [J]. Antimicrob Agents Chemother. 2008;52(6):2226\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"16","key":"12869_CR23","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","volume":"367","author":"M Lee","year":"2012","unstructured":"Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis [J]. N Engl J Med. 2012;367(16):1508\u201318.","journal-title":"N Engl J Med"},{"issue":"5","key":"12869_CR24","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1128\/AAC.06227-11","volume":"56","author":"P Beckert","year":"2012","unstructured":"Beckert P, Hillemann D, Kohl TA, et al. RplC T460C identified as a dominant mutation in linezolid-resistant Mycobacterium tuberculosis strains [J]. Antimicrob Agents Chemother. 2012;56(5):2743\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"12869_CR25","first-page":"28","volume":"26","author":"ZH Tang","year":"2018","unstructured":"Tang ZH, Chen L. Progress on drug resistance related genes of Mycobacterium tuberculosis to linezolid [J]. Practical J Cardiac Cereb Pneumal Vascular Disease. 2018;26(11):28\u201331.","journal-title":"Practical J Cardiac Cereb Pneumal Vascular Disease"},{"key":"12869_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mimet.2018.08.011","volume":"153","author":"N Ismail","year":"2018","unstructured":"Ismail N, Omar SV, Ismail NA, et al. In vitro approaches for generation of Mycobacterium tuberculosis mutants resistant to bedaquiline, Clofazimine or linezolid and identification of associated genetic variants [J]. J Microbiol Meth. 2018;153:1\u20139.","journal-title":"J Microbiol Meth"},{"key":"12869_CR27","unstructured":"Tang ZH. The research of association between gene mutation and linezolid resistance in mycobacterium [D]. Zunyi; Zunyi Medical University; 2019."},{"issue":"1","key":"12869_CR28","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13756-021-00995-8","volume":"10","author":"C Yao","year":"2021","unstructured":"Yao C, Guo H, Li Q, et al. Prevalence of extensively drug-resistant tuberculosis in a Chinese multidrug-resistant TB cohort after redefinition [J]. Antimicrob Resist Infect Control. 2021;10(1):126.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"5","key":"12869_CR29","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1046\/j.1365-2958.2002.03242.x","volume":"46","author":"P Sander","year":"2002","unstructured":"Sander P, Belova L, Kidan YG, et al. Ribosomal and non-ribosomal resistance to oxazolidinones: species-specific idiosyncrasy of ribosomal alterations [J]. Mol Microbiol. 2002;46(5):1295\u2013304.","journal-title":"Mol Microbiol"},{"issue":"6","key":"12869_CR30","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1159\/000109769","volume":"53","author":"I Escribano","year":"2007","unstructured":"Escribano I, Rodr\u00edguez JC, Llorca B, et al. Importance of the efflux pump systems in the resistance of Mycobacterium tuberculosis to fluoroquinolones and linezolid [J]. Chemotherapy. 2007;53(6):397\u2013401.","journal-title":"Chemotherapy"},{"issue":"5","key":"12869_CR31","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1159\/000226425","volume":"55","author":"AA Velayati","year":"2009","unstructured":"Velayati AA, Farnia P, Ibrahim TA, et al. Differences in cell wall thickness between resistant and nonresistant strains of Mycobacterium tuberculosis: using transmission electron microscopy [J]. Chemotherapy. 2009;55(5):303\u20137.","journal-title":"Chemotherapy"},{"issue":"6","key":"12869_CR32","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3390\/ph16060784","volume":"16","author":"WC Gan","year":"2023","unstructured":"Gan WC, Ng HF, Ngeow YF. Mechanisms of linezolid resistance in mycobacteria [J]. Pharmaceuticals (Basel). 2023;16(6):784.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"12869_CR33","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1128\/AAC.00037-14","volume":"58","author":"RC Hartkoorn","year":"2014","unstructured":"Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between Clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis [J]. Antimicrob Agents Chemother. 2014;58(5):2979\u201381.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"12869_CR34","doi-asserted-by":"publisher","first-page":"e0219923","DOI":"10.1128\/spectrum.02199-23","volume":"11","author":"DA Negatu","year":"2023","unstructured":"Negatu DA, Aragaw WW, Dartois V, et al. Characterization of in vitro resistance to linezolid in Mycobacterium abscessus [J]. Microbiol Spectr. 2023;11(4):e0219923.","journal-title":"Microbiol Spectr"},{"issue":"1","key":"12869_CR35","doi-asserted-by":"publisher","first-page":"e02919","DOI":"10.1128\/JCM.02919-20","volume":"60","author":"K Kaniga","year":"2022","unstructured":"Kaniga K, Hasan R, Jou R, et al. Bedaquiline drug resistance emergence assessment in multidrug-resistant tuberculosis (MDR-TB): a 5-Year prospective in vitro surveillance study of bedaquiline and other second-line drug susceptibility testing in MDR-TB isolates [J]. J Clin Microbiol. 2022;60(1):e02919\u201320.","journal-title":"J Clin Microbiol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-12869-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12869-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12869-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T12:59:37Z","timestamp":1773233977000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-12869-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12869"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-12869-8","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]},"assertion":[{"value":"5 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Institutional Review Board of Beijing Chest Hospital (protocol no. YJS-2020-012; approved on September 16, 2020) and was conducted in accordance with the Declaration of Helsinki. The ethics committee granted a waiver of individual informed consent as the research involved no more than minimal risk and used existing archived bacterial isolates and completely anonymized clinical data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"541"}}